-
Natera, Inc. v. ArcherDX, Inc. DC CAFC
- 1:20-cv-00125
- D. Del.
- Judge: Gregory B. Williams
- Filed: 01/27/2020
- Latest Docket Entry: 03/01/2024
- PACER
- Docket updated daily
1
Plaintiff
2
Defendants
5
Accused
Products
5
Patents-in-Suit
1,552
Days in
Litigation
-
Natera, Inc. v. ArcherDX, Inc. DC CAFC
- 1:20-cv-00125
- D. Del.
- Judge: Gregory B. Williams
- Filed: 01/27/2020
- Latest Docket Entry: 03/01/2024
- PACER
- Docket updated daily
Causes of Action
Infringement
Declaratory Judgment
Patent Infringement
Market Sector
Biotech and Pharma
Court
Assigned Judge
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A method for amplifying and sequencing DNA, comprising:isolating cell-free DNA from a biological sample and tagging the isolated cell-free DNA, wherein each tagged DNA molecule comprises a molecular barcode;performing a first PCR to simultaneously
view more
|
Valid
Entry 665 Entry 609 |
6 |
The method of claim 1, wherein the first PCR comprises simultaneously amplifying at least 100 target loci using the universal primer and at least 100 target-specific primers in a single reaction volume.
|
Valid
Entry 665 Entry 609 |
8 |
The method of claim 1, wherein the second PCR comprises simultaneously amplifying at least 100 target loci using the universal primer and at least 100 inner target-specific primers in a single reaction volume.
|
Valid
Entry 665 Entry 609 |
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A method of amplifying target loci in a nucleic acid sample, the method comprising:contacting the nucleic acid sample comprising target loci with a library of at least 2 primers that simultaneously hybridize to at least 2 of the target loci to
view more
|
Valid
Entry 665 Entry 609 |
19 |
The method of claim 1, wherein the nucleic acid sample comprises cell-free DNA, and wherein the cell-free DNA comprises tumor DNA.
|
Valid
Entry 665 Entry 609 |
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A method for amplifying and sequencing DNA, comprising:ligating adaptors to cell-free DNA isolated from a biological sample, wherein the adaptors each comprises a universal priming sequence and a molecular barcode;performing a first PCR to
view more
|
Valid
Entry 665 Entry 609 |
3 |
The method of claim 1, wherein the method comprises subjecting the isolated cell-free DNA to blunting ending, dA-tailing, and adaptor ligation.
|
Valid
Entry 665 Entry 609 |
4 |
The method of claim 1, wherein the second PCR is one-sided nested PCR.
|
Valid
Entry 665 Entry 609 |
6 |
The method of claim 1, wherein the first PCR comprises simultaneously amplifying between 100 and 5,000 target loci using the first universal primer and between 100 and 5,000 target specific primers in a single reaction volume.
|
Valid
Entry 665 Entry 609 |
7 |
The method of claim 6, wherein the second PCR comprises simultaneously amplifying between 100 and 5,000 target loci using the second universal primer and between 100 and 5,000 target-specific primers in a single reaction volume.
|
Valid
Entry 665 Entry 609 |
-
Infringement
ArcherDX, LLC
- 3 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
ArcherMETFusionPlexPersonalized Cancer Monitoring (“PCM”)STRATAFIDEVariantPlex | US 10,557,172 B2 |
1, 6, 8
|
Infringement
Entry 665Entry 609 |
ArcherMETFusionPlexPersonalized Cancer Monitoring (“PCM”)STRATAFIDEVariantPlex | US 10,597,708 B2 |
1, 19
|
Infringement
Entry 665Entry 609 |
ArcherMETFusionPlexPersonalized Cancer Monitoring (“PCM”)STRATAFIDEVariantPlex | US 10,731,220 B2 |
1, 3, 4, 6, 7
|
Infringement
Entry 665Entry 609 |
Invitae Corporation
- 3 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
ArcherMETFusionPlexPersonalized Cancer Monitoring (“PCM”)STRATAFIDEVariantPlex | US 10,557,172 B2 |
1, 6, 8
|
Infringement
Entry 665Entry 609 |
ArcherMETFusionPlexPersonalized Cancer Monitoring (“PCM”)STRATAFIDEVariantPlex | US 10,597,708 B2 |
1, 19
|
Infringement
Entry 665Entry 609 |
ArcherMETFusionPlexPersonalized Cancer Monitoring (“PCM”)STRATAFIDEVariantPlex | US 10,731,220 B2 |
1, 3, 4, 6, 7
|
Infringement
Entry 665Entry 609 |
-
Damages